A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 24, 2018

Primary Completion Date

June 1, 2018

Study Completion Date

June 4, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

AG-348

120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled \[14C\]AG-348.

DRUG

[13C6]AG-348

IV microdose of approximately 100 micrograms (mcg), single dose.

Trial Locations (1)

Covance, Madison